The European Medicines Agency has recommended granting a conditional marketing authorization for ImmunityBio, Inc.‘s (NASDAQ: IBRX) Anktiva (nogapendekin alfa inbakicept) in combination with Bacillus ...

Editor's Note: This is an excerpt from WBUR's weekly health newsletter, CommonHealth. If you like what you read and want it in your inbox, sign up here. Bladder cancer hits men especially hard. The ...

A new drug delivery device, TAR-200, has shown remarkable success against one of the most stubborn forms of bladder cancer, eliminating tumors in over 80% of patients whose disease resisted previous ...

Bladder control problems affect an estimated 43 million – or one in six – U.S. adults. Of those, nearly 16 million people have urge urinary incontinence, a common symptom of overactive bladder (OAB) ...

Both a smartphone app and a telehealth visit helped female veterans manage urinary incontinence The app produced earlier results, but ultimately both approaches were equally effective THURSDAY, Sept.

After decades of limited options, a groundbreaking FDA-approved treatment is opening new doors for people with certain types of bladder cancer. Supported by Johnson & Johnson Bill is a real patient ...

The US Food and Drug Administration has approved Johnson & Johnson’s drug delivery system for a type of bladder cancer, offering a potential surgery-free option for patients. The drug release system, ...

The appropriate duration of anticoagulation for venous thromboembolism (VTE) in patients who have a transient provoking factor (e.g., surgery, trauma, or immobility) and concomitant enduring risk ...

Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...